ITRM

Iterum Therapeutics plc (NASDAQ:ITRM) is a clinical-stage pharmaceutical company founded in 2015 and headquartered in Dublin, Ireland. The company focuses on developing and commercializing anti-infective treatments, with its lead product being sulopenem, a novel antibiotic compound. After years of clinical development, Iterum achieved a significant milestone in October 2024 when the U.S. Food and Drug Administration approved its oral sulopenem product, marketed as <b>ORLYNVAH</b>, making it the first and only oral penem antibiotic approved in the United States. The company is currently preparing for commercial launch while simultaneously exploring strategic alternatives including potential sale or licensing of its product rights.